MedTrace Logo

Vaccination Against COVID-19 in Pregnant and Lactating Women in Belgium

NCT05618548 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2022-11-16

No results posted yet for this study

Summary

This study will investigate whether pregnant and lactating women can develop similar protective immunity as non-pregnant women against Coronavirus Infectious Disease 2019 (COVID-19) upon vaccination, without safety issues. Immunogenicity and safety of all currently licensed COVID-19 vaccines that are administered to pregnant and lactating women in Belgium will be studied.

Conditions

  • Covid19

Interventions

BIOLOGICAL

COVID-19 vaccine

COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).

Sponsors & Collaborators

  • Vrije Universiteit Brussel

    collaborator OTHER

  • Sciensano

    collaborator OTHER_GOV

  • Université Libre de Bruxelles

    collaborator OTHER

  • Universiteit Antwerpen

    lead OTHER

Principal Investigators

  • Elke Leuridan, MD, PhD · Universiteit Antwerpen

  • Kirsten Maertens, PhD · Universiteit Antwerpen

  • Larissa De Brabandere, MD · Universiteit Antwerpen

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-12-31
Completion
2023-06-30
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05618548 on ClinicalTrials.gov